# RATIONALE-315 (NCT04379635)

> Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

- Drugs tested: tislelizumab
- Indication: resectable stage II–IIIA non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04379635
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: BeiGene
- Conditions: Non Small Cell Lung Cancer
- Interventions: Tislelizumab; Cisplatin injection; Paclitaxel injection; Pemetrexed Disodium; Placebos; Carboplatin
- Enrollment: 453
- Primary outcome: Major pathological response (MPR) in Intent-to-Treat (ITT) analysis set
- Primary outcome: Event-free survival (EFS) in ITT analysis set as Assessed by the Blinded Independent Central Review (BICR)

## Questions raised in the commentary

_Automated from the 37 newest of 39 indexed sources (Oct 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether adjuvant immunotherapy adds value, and which patients can forgo it
- How biomarkers, including PD-L1, can guide treatment selection
- How MRD or ctDNA could guide treatment decisions
- How pathological response should be assessed and interpreted

Also discussed: cross-trial comparisons.

## Indexed commentary on RATIONALE-315 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 33
- YouTube: 3
- Podcasts: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=rationale-315-nct04379635

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04379635", "email": "<work email>"}; the inbox owner confirms by the emailed link.